1. Report Overview

1.1 Overview of the Global Women’s Healthcare Market

1.2 Why You Should Read This Report

1.3 How This Report Delivers

1.4 Key Questions Answered by This Analytical Report Include:

1.5 Who is This Report For?

1.6 Methodology

1.6.1 Primary Research

1.6.2 Secondary Research

1.6.3 Market Evaluation & Forecasting Methodology

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Visiongain Reports

1.9 About Visiongain

2. Introduction to the Woman’s Health Issue

2.1 What are the major women’s health issues?

2.2 What are the causes and risk factors of women’s health issues?

2.2.1 Modern Urbanization

2.2.1.1 Alcohol Intake:

2.2.1.2 Smoking:

2.2.1.3 Unhealthy diet

2.2.2 Social Restriction and Emotional Factors

2.2.3 Pregnancy

2.2.4 Malnutrition

2.2.5 Obesity

2.2.6 Age

2.3 Diagnosis of Women’s Health Issues

2.3.1 Diagnosis of Breast Cancer

2.3.2 Diagnosis of Osteoporosis

2.3.3 Diagnosis of Endometriosis

2.3.4 Diagnosis of polycystic ovary syndrome

2.3.4.1 Ultrasound

2.3.4.2 Hormonal blood tests

2.3.4.3 Other blood tests

2.4 Epidemiology of Women’s diseases

2.4.1 Epidemiology of Postmenopausal Osteoporosis:

2.4.1.1 Projections:

2.4.2 Epidemiology of Infertility in Women:

2.4.3 Epidemiology of Endometriosis:

2.4.4 Epidemiology of polycystic ovary syndrome

2.5 Humanistic and Economic Burden

2.5.1 Mortality

2.5.2 Morbidity

2.5.2.1 Years of Life Lost(YLL)

2.5.2.1.1 Cardiovascular Disease

2.5.2.1.2 Dyslipidaemia

2.5.2.1.3 Hypertension

2.5.2.1.4 Obesity

2.5.2.1.5 Depression

2.5.3 Economic Impact

2.6 Women’s Health Issues: Prevention and Treatment

2.6.1 Lifestyle changes

2.6.2 Pharmacotherapy

2.6.3 Other treatments

3. Introduction to the Global Women Healthcare Market

3.1 Global Women’s Healthcare Market by Application

3.1.1 Postmenopausal Osteoporosis

3.1.2 Hormonal Contraceptives

3.1.3 Menopause

3.1.4 Infertility

3.1.5 Endometriosis

3.1.6 Polycystic Ovary Syndrome

4. Global Women’s Healthcare Market Size and Forecast 2017-2027

4.1 Market Segmentation by Application

4.1.1 Global Postmenopausal Osteoporosis Market

4.1.1.1 Market Overview

4.1.1.2 Market Size and Forecast

4.1.1.3 Competitive Analysis

4.1.1.4 SWOT Analysis of the Global Postmenopausal Osteoporosis Drugs Market

4.1.2 Global Hormonal Contraceptives Market

4.1.2.1 Market Overview

4.1.2.2 Market Size and Forecast

4.1.2.3 Competitive Analysis

4.1.2.4 SWOT Analysis of the Global Hormonal Contraceptives Market

4.1.3 Global Menopause Market

4.1.3.1 Market Overview

4.1.3.2 Market Size and Forecast

4.1.3.3 Competitive Analysis

4.1.3.4 SWOT Analysis of the Global Menopause Market

4.1.4 Global Infertility Market

4.1.4.1 Market Overview

4.1.4.2 Market Size and Forecast

4.1.4.3 Competitive Analysis

4.1.4.4 SWOT Analysis of Global Infertility Market

4.1.5 Global Endometriosis Market

4.1.5.1 Market Overview

4.1.5.2 Market Size and Forecast

4.1.5.3 Competitive Analysis

4.1.5.4 SWOT Analysis of the Global Endometriosis Market

4.1.6 Global Polycystic Ovary Syndrome Market

4.1.6.1 Market Overview

4.1.6.2 Market Size and Forecast

4.1.6.3 Competitive Analysis

4.1.6.4 SWOT Analysis of Global Polycystic Ovary Syndrome Market

4.2 Leading Women Healthcare Products, 2016

5. Leading National Markets Forecast 2017-2027

5.1 Geographical Breakdown of Global Women’s Healthcare Drugs Market, 2016

5.1 Women’s Healthcare Drugs Market in the US and Latin America, 2016

5.1.1 Market Forecast of the US and Latin America, 2017-2027

5.2 Women’s Healthcare Drugs Market in the EU5, 2016

5.2.1 Market Forecast of the EU5 Countries, 2017-2027

5.2.1.1 The UK

5.2.1.2 Germany

5.2.1.3 France

5.2.1.4 Spain

5.2.1.5 Italy

5.3 Women’s Healthcare Drugs Market in the Rest of Europe, 2016

5.4 Women’s Healthcare Drugs Market in the Japan, 2016

5.5 Women’s Healthcare Drugs Market in the Rest of the World, 2016

6. Global Women’s Healthcare Market Growth Drivers

6.1 Increase in Aging Female Population

6.2 Expected Launch of Promising Pipeline Molecules

6.3 Growing Prevalence of Postmenopausal Osteoporosis

6.4 Introduction of Technologically Advanced Products

7. Global Women’s Healthcare Market Challenges

7.1 Patent Expiry of Major Blockbuster Drugs

7.2 Lack of Effective Treatments

7.3 Threat of Substitution by Alternative Treatment Options

7.4 High Cost of MRT Therapies

8. Global Women’s Healthcare Market Trends

8.1 Rise in Strategic Partnerships

8.2 Awareness Programs and Initiatives

8.3 Paradigm Shift to Non-Hormonal Therapies

9. Pipeline Molecules

10. Leading Companies in the Global Women’s Healthcare Market, 2016

10.1 Bayer

10.1.1 Bayer: Sales by Geography 2016

10.1.2 Presence in the Women’s Healthcare market

10.1.3 SWOT Analysis

10.2 Eli Lily and Company

10.2.1 Eli Lily: Sales by Geography 2016

10.2.2 Collaboration Agreement with Pfizer

10.2.3 SWOT Analysis

10.3 Merck & Co., Inc.

10.3.1 Merck & Co.: Sales by Geography

10.3.2 SWOT Analysis

10.4 Pfizer Inc.

10.4.1 Pfizer: Sales by Geography 2016

10.4.2 Collaboration Agreement with Eli Lily and Company

10.4.3 SWOT Analysis

10.5 Novartis

10.5.1 SWOT Analysis

10.6 Sanofi

10.6.1 SWOT Analysis

10.7 Amgen

10.7.1 SWOT Analysis

10.8 Novo Nordisk

10.8.1 SWOT Analysis

10.9 AbbVie

10.9.1 SWOT Analysis

10.10 Bristol-Myers Squibb

10.10.1 SWOT Analysis

10.11 Other Prominent Vendors in Women’s Healthcare Market

11. Conclusions

Appendices

Glossary

Associated Visiongain Reports

Visiongain Report Sales Order Form

Appendix A

About Visiongain

Appendix B

Visiongain report evaluation form

List of Tables

Table 2.1 Major women’s health issue

Table 2.2 Women’s Health Drugs (Company and Product)

Table 4.1 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.2 Global Postmenopausal Osteoporosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.3 Global Hormonal Contraceptives Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.4 Global Menopause Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.5 Global Infertility Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.6 Global Endometriosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.7 Global Polycystic Ovary Syndrome Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 4.8 Revenues of the Leading Women Healthcare Products, 2016

Table 5.1 Global Women’s Healthcare Drugs Market by Region: Revenue ($m), and Market Share (%), 2016

Table 5.2 Global Women’s Healthcare Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.3 Global Women’s Healthcare Drugs Market by Region: AGR (%), 2016-2027

Table 5.4 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2017-2027 (%)

Table 5.5 Women’s Healthcare Drugs Market Forecast in the US 2016-2027: Revenue ($m), AGR (%), CAGR (%)

Table 5.6 Women’s Healthcare Drugs Market Forecast in the EU5 2016-2027: Revenue ($m), Global Market Share (%), EU5 Market Share (%)

Table 5.7 Women’s Healthcare Drugs Market Forecast in EU5: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.8 Women’s Healthcare Drugs Market Forecast in the UK: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.9 Women’s Healthcare Drugs Market Forecast in Germany: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.10 Women’s Healthcare Drugs Market Forecast in France: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.11 Women’s Healthcare Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.12 Women’s Healthcare Drugs Market Forecast in Italy: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.13 Women’s Healthcare Drugs Market Forecast in RoE: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.14 Women’s Healthcare Drugs Market Forecast in Japan: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 5.15 Women’s Healthcare Drugs Market Forecast in Row: Revenue ($m), AGR (%), CAGR (%), 2016-2027

Table 9.1: Active Pipeline Molecules under Development for Treating Epilepsy

Table 10.1 Bayer: Overview 2016

Table 10.2 Bayer: Pipeline

Table 10.3 Eli Lilly and Company: Overview 2016

Table 10.4 Merck: Overview 2016

Table 10.5 Pfizer: Overview 2016

Table 10.6 Pfizer: Pipeline

Table 10.7 Novartis: Overview 2016

Table 10.8 Novartis: Pipeline

Table 10.9 Sanofi: Overview 2016

Table 10.10 Amgen: Overview 2016

Table 10.11 Novo Nordisk: Overview 2016

Table 10.12 AbbVie: Overview 2016

Table 10.13 Bristol-Myers Squibb: Overview 2016

Table 10.14 Bristol-Myers Squibb: Overview 2016

List of Figures

Figure 1.1 Global Women's Health Market Segmentation by Application

Figure 2.1 Percentage of Women Affected by Endometriosis

Figure 2.2 DALY’s due to Obesity in G7 and BRIC Nation: Absolute Number (million), 2015

Figure 3.1 Global Women’s Health Market Segmentation by Application (%), 2016

Figure 4.1 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.2 Global Postmenopausal Osteoporosis Drugs Market Segmentation by Line of Therapy (%),2016

Figure 4.3 Global Postmenopausal Osteoporosis Drugs Market Segmentation by Line of Therapy (million), 2016

Figure 4.4 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.5 SWOT Analysis of the Global Postmenopausal Osteoporosis Drugs Market

Figure 4.6 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.7 SWOT Analysis of the Global Hormonal Contraceptives Market

Figure 4.8 Global Menopause Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.9 SWOT Analysis of the Global Menopause Market

Figure 4.10 Global Infertility Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.11 SWOT Analysis of the Global Infertility Market

Figure 4.12 Global Endometriosis Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.13 SWOT Analysis of the Global Endometriosis Market

Figure 4.14 Global Polycystic Ovary Syndrome Market by Class of Drugs (%), 2016

Figure 4.15 Global Polycystic Ovary Syndrome Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)

Figure 4.16 SWOT Analysis of the Global Polycystic Ovary Syndrome Market

Figure 4.17 Market Share (%) of the Leading Women Healthcare Products, 2016

Figure 5.1 Global Women’s Healthcare Drugs Market by Region: Revenue ($m), 2016

Figure 5.2 Global Women’s Healthcare Drugs Market by Region: Market Share (%), 2016

Figure 5.3 Global Women’s Healthcare Drugs Market by Region: AGR 2016-2027 (%)

Figure 5.4 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2017-2027 (%)

Figure 5.5 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2016 (%)

Figure 5.6 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2022 (%)

Figure 5.7 Global Women’s Healthcare Drugs Market by Region: Market Share Forecast 2027 (%)

Figure 5.8 Women’s Healthcare

Figure 5.9 Women’s Healthcare Drugs Market in EU5 by Country: Global Market Share (%), 2016

Figure 5.10 Women’s Healthcare Drugs Market in EU5 Countries: EU5 Market Share (%), 2016

Figure 5.11 Women’s Healthcare Drugs Market Forecast in EU5: Revenue ($m), AGR (%),2016-2027

Figure 5.12 Women’s Healthcare Drugs Market Forecast in the UK: Revenue ($m), AGR (%),2016-2027

Figure 5.13 Women’s Healthcare Drugs Market Forecast in Germany: Revenue ($m), AGR (%),2016-2027

Figure 5.14 Women’s Healthcare Drugs Market Forecast in France: Revenue ($m), AGR (%),2016-2027

Figure 5.15 Women’s Healthcare Drugs Market Forecast in Spain: Revenue ($m), AGR (%),2016-2027

Figure 5.16 Women’s Healthcare Drugs Market Forecast in Italy: Revenue ($m), AGR (%),2016-2027

Figure 5.17 Women’s Healthcare Drugs Market Forecast in the RoE: Revenue ($m), AGR (%),2016-2027

Figure 5.18 Women’s Healthcare Drugs Market Forecast in Japan: Revenue ($m), AGR (%), 2016-2027

Figure 5.19 Women’s Healthcare Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2016-2027

Figure 10.1 Bayer: Sales by Geography (%), 2016

Figure 10.2 Bayer: SWOT Analysis

Figure 10.3 Eli Lilly: Sales by Geography (%), 2016

Figure 10.4 Eli Lilly: SWOT Analysis

Figure 10.5 Merck & Co.: Sales by Geography (%), 2016

Figure 10.6 Merck & Co.: SWOT Analysis

Figure 10.7 Pfizer: Sales by Geography (%), 2016

Figure 10.8 Pfizer: SWOT Analysis

Figure 10.9 Novartis: SWOT Analysis

Figure 10.10 Sanofi: SWOT Analysis

Figure 10.11 Sanofi: SWOT Analysis

Figure 10.12 Novo Nordisk: Sales by Geography (%), 2016

Figure 10.13 AbbVie: SWOT Analysis

Figure 10.14 Bristol-Myers Squibb: SWOT Analysis

Figure 11.1 Global Women’s Healthcare Drugs Market Forecast 2016-2027: Revenue ($m), AGR (%)